secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pelthos Therapeutics Inc. (PTHS)
CIK:        0001919246
Form:       8-K
Filed at:   2026-10-01T21:15:10+00:00
Accession:  0001919246-26-000125
Event type: other_material
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Pelthos holders re-elect 8 directors, approve 2026 equity plan with 500,000-share reserve
--------------------------------------------------------------------------------

- Eight director nominees elected at the Sept 29, 2026 annual meeting; Matthew Pauls received the most withheld votes: 110,700 vs 2,775,221 for.
- Grant Thornton LLP ratified as independent auditor for fiscal 2026: 3,394,740 votes for, 1 against and 1,353 abstaining.
- 2026 Equity Incentive Plan approved with 2,698,543 votes for, 187,365 against and 13 abstaining; it replaces the 2023 plan and reserves 500,000 shares plus a 5% annual evergreen increase.
- Record date Aug 4, 2026: 3,828,469 common shares and 52,128 Series A preferred outstanding; 3,396,094 votes present (70.0%) constituted a quorum.
- Non-employee director compensation capped at $750,000 per fiscal year ($1,000,000 in initial service year); forfeited shares can be reissued under the plan.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1919246/000191924626000125/0001919246-26-000125-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1919246/000191924626000125/pths-20260929.htm
  HTML page:      https://secwatch.observer/filing/0001919246-26-000125

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer